Business

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

LAS VEGAS--(BUSINESS WIRE)-- PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and

articlePharmacyte Biotech, Inc.April 27, 20224/company/pharmacyte-biotech-inc/news/pharmacyte-biotech-to-attend-15th-international-conference-on-advanced-technologies-and-treatments-for-diabetes
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

About this update from Pharmacyte Biotech, Inc.

[{"type":"text","content":" LAS VEGAS--(BUSINESS WIRE)--\nPharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that the management team will be attending the 15th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) held April 27-30, 2022, in Barcelona, Spain. ATTD is a scientific conference that was established in 2008. The meetings at the conference have become the most renowned forum worldwide for presenting developments in new diabetes technologies and treatments.\n\nPharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, said, “This annual conference is where clinicians, diabetes care providers, researchers, industry leaders and investors come together to share knowledge and develop collaborations. As we continue to broaden our product portfolio, the development of a treatment for Type 1 and insulin-dependent Type 2 diabetes that can essentially serve as an ‘artificial pancreas’ is vitally important to PharmaCyte. Our live-cell encapsulation-based treatment offers real hope for future development in the field of diabetes.”\n\nMain topics being discussed during the conference include decision support systems, data and artificial intelligence based decision support systems, closed-loop systems and algorithms, artificial pancreas, insulin pumps, glucose sensors, implantable pumps and sensors, new insulin analogs and new insulin delivery systems, devices focused on diabetic preventions, informatics in the service of medicine; telemedicine, software and other technologies, advanced medical technologies to be used in hospitals and more.\n\nIn addition to attending presentations and discussions by distinguished professionals in the field, PharmaCyte’s management team will meet with members of its International Diabetes Consortium to launch its new diabetes endeavors.\n\nTo learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced inoperable pancreatic cancer, we encourage you to watch the company’s documentary video complete with medical animations at: https://www.PharmaCyte.com/Cancer\n\nAbout PharmaCyte Biotech\n\nPharmaCyte Biotech, Inc. is a biotechnology company developing cellular therapies for ca...

More updates from Pharmacyte Biotech, Inc.